NeuroVive Pharmaceutical and to-BBB, the Dutch drug brain delivery company, are entering into a joint program to develop therapies for stroke and other acute neurodegenerative diseases by combining their technologies.
NeuroVive Pharmaceutical is engaged in research and development of nerve cell-protecting and regenerative cyclosporin-based pharmaceuticals for the treatment of traumatic brain injuries (TBI) and other neurological diseases. The Company’s first product NeuroSTAT®, is a novel, cremophor-free, cyclosporin-A lipid emulsion.
“The collaboration with to-BBB opens up the possibility of treating brain disorders beyond TBI. There is a tremendous unmet medical need in treating patients with acute neurodegeneration such as stroke, cardiac-arrest-induced brain damage and spinal cord injuries, where one can expect the blood-brain barrier (BBB) to significantly prevent drug penetration to the central nervous system (CNS)”, says Dr Eskil Elmér, CSO of NeuroVive.
Pieter Gaillard, CSO of to-BBB, adds: “The BBB is indeed a significant obstacle in the treatment of CNS disorders. to-BBB’s proprietary G-Technology® can safely enhance drug delivery to the brain and we are excited to address this with NeuroVive’s cyclosporin-based pharmaceuticals”.
“Currently there are no approved pharmacological or cellular primary neuroprotective treatments for stroke and spinal cord injuries. Consequently, the need to develop treatment for acute degenerative disorders has never been greater than it is today. The deal with to-BBB has the potential to generate drugs for large markets in CNS diseases such as stroke”, says Mikael Brönnegård, CEO of NeuroVive.
“We are very pleased to collaborate with NeuroVive,” says Willem van Weperen, CEO of to-BBB. We are convinced that synergies in research and clinical platforms as well as business and commercial strategies between to-BBB and NeuroVive will result in a very strong partnership that will benefit patients with these devastating CNS diseases”.
NeuroVive is funding the initial development up to preclinical Proof of Concept, after which the two companies have agreed to develop and commercialize the product jointly.
About NeuroVive
NeuroVive Pharmaceutical AB is a Swedish drug development company. NeuroVive’s primary mission is to develop drugs which protect nerve cells. The company is currently conducting clinical trials with NeuroSTAT®. In addition to introducing NeuroSTAT® as the first cyclophilin-D-inhibiting mitochondrial protectant, NeuroVive is researching and developing variants of cyclophilin-inhibiting cyclosporins and new ways of transporting these drugs across the blood-brain barrier to the central nervous system. NeuroVive Pharmaceutical AB (publ) shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses and offers an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.
About to-BBB
to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.
to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.
Contact
Mikael Brönnegård, MD., PhD,
Chief Executive Officer
Phone: +46 46 2880110
Mobile: +46 702996264
E-mail: mikael.bronnegard@neurovive.com
NeuroVive Pharmaceutical AB (publ)
Biomedical Center BMC D10
221 84 Lund, Sweden
www.neurovive.com
Eskil Elmér, MD., PhD,
Chief Scientific Officer
Email: eskil.elmer@neurovive.com
Mobile: +46 733919601
Phone: +46 46 2880110
NeuroVive Pharmaceutical AB (publ)
Biomedical Center BMC D10
221 84 Lund, Sweden
www.neurovive.com
Willem van Weperen, MSc, MBA
Chief Executive Officer
Phone: +31 71 3322252
Mobile: +31 634 054812
E-mail: vanweperen@toBBB.com
Pieter Gaillard, PhD
Chief Scientific Officer
Phone: +31 71 3322251
Mobile: +31 621 525000
E-mail: gaillard@toBBB.com
to-BBB technologies BV
Niels Bohrweg 11, 2333 CA Leiden
BioScience Park Leiden
Bio Partner Center II
The Netherlands
www.toBBB.com
to-BBB technologies BV
Niels Bohrweg 11, 2333 CA Leiden
BioScience Park Leiden
Bio Partner Center II
The Netherlands
www.toBBB.com